SHANGHAI – In a case that has caused a stir among the community of returnee research scientists and even the wider drug-buying public, the U.S. attorney's office has taken the unusual move of requesting a federal judge to dismiss criminal charges filed against two former Eli Lilly and Co. employees of Chinese ethnicity working in the U.S. Read More
SHANGHAI – Generon Corp. Ltd., believed to be the first Chinese biotech to complete a phase II global trial for a biologic, has announced the results for its lead candidate, F-627 (benegrastim), a next-generation drug to Amgen Inc.'s Neulasta (pegfilgrastim) for the treatment of neutropenia. Read More
HONG KONG – Early oral administration of an immune modulator that is normally used for treatment of relapsing multiple sclerosis (MS) significantly reduced brain inflammation and improved the clinical outcomes of acute ischemic stroke (AIS) patients enrolled in a small, early phase pilot study conducted in China. Read More
TOKYO – Japanese authorities are stepping up their push to become more transparent by working with foreign companies in the health care product market. Read More
Zydus Cadila Group, of New Delhi, India, said it launched a biosimilar of Humira (adalimumab, Abbvie Inc.) in India for rheumatoid arthritis and other autoimmune disorders. Zydus will market the product as Exemptia. Read More
